Citation: | Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of long-term complications of renal transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(6): 661-666, 671. doi: 10.3969/j.issn.1674-7445.2019.06.005 |
[1] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志, 2012, 40(5):353-367. DOI:10. 3760/cma.j.issn.0253-3758.2012.05.001.
Branch of Cardiovascular Diseases of Chinese Medical Association, Editorial Committee of Chinese Journal of Cardiology. Guidelines for diagnosis and treatment of non-ST-segment elevation acute coronary syndrome[J]. Chin J Cardiol, 2012, 40(5):353-367. DOI: 10.3760/cma.j.issn.0253-3758.2012.05.001.
|
[2] |
AMSTERDAM EA, WENGER NK, BRINDIS RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 64(24):e139-e228. DOI: 10.1016/j.jacc.2014.09.017.
|
[3] |
LEVINE GN, BATES ER, BITTL JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. J Thorac Cardiovasc Surg, 2016, 152(5):1243-1275. DOI: 10.1016/j.jtcvs.2016.07.044.
|
[4] |
ROFFI M, PATRONO C, COLLET JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(3):267-315. DOI: 10.1093/eurheartj/ehv320.
|
[5] |
DEVEREAUX PJ, XAVIER D, POGUE J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study[J]. Ann Intern Med, 2011, 154(8):523-528. DOI: 10.7326/0003-4819-154-8-201104190-00003.
|
[6] |
IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177. DOI: 10.1093/eurheartj/ehx393.
|
[7] |
KASISKE BL, MACLEAN JR, SNYDER JJ. Acute myocardial infarction and kidney transplantation[J]. J Am Soc Nephrol, 2006, 17(3):900-907. doi: 10.1681/ASN.2005090984
|
[8] |
LENTINE KL, BRENNAN DC, SCHNITZLER MA. Incidence and predictors of myocardial infarction after kidney transplantation[J]. J Am Soc Nephrol, 2005, 16(2):496-506. doi: 10.1681/ASN.2004070580
|
[9] |
KABORÉ R, HALLER MC, HARAMBAT J, et al. Risk prediction models for graft failure in kidney transplantation: a systematic review[J]. Nephrol Dial Transplant, 2017, 32(suppl 2):ii68-ii76. DOI: 10.1093/ndt/gfw405.
|
[10] |
朱有华, 石炳毅.肾脏移植手册[M].北京:人民卫生出版社, 2010.
|
[11] |
黎磊石.中国肾移植手册[M]. 2版.香港:华夏科学出版社, 2009.
|
[12] |
XIAO D, CRAIG JC, CHAPMAN JR, et al. Donor cancer transmission in kidney transplantation: a systematic review[J]. Am J Transplant, 2013, 13(10):2645-2652. DOI: 10.1111/ajt.12430.
|
[13] |
WONG G, TURNER RM, CHAPMAN JR, et al. Time on dialysis and cancer risk after kidney transplantation[J]. Transplantation, 2013, 95(1):114-121. DOI: 10.1097/TP.0b013e31827743b4.
|
[14] |
MA MK, LIM WH, TURNER RM, et al. The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis[J]. Transplantation, 2014, 98(12):1286-1293. DOI: 10.1097/TP.0000000000000375.
|
[15] |
VAN LEEUWEN MT, WEBSTER AC, MCCREDIE MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study[J]. BMJ, 2010, 340:c570. DOI: 10.1136/bmj.c570.
|
[16] |
HIBBERD AD, TREVILLIAN PR, WLODARCZYK JH, et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study[J]. Transplantation, 2013, 95(1):122-127. DOI: 10.1097/TP.0b013e3182782f59.
|
[17] |
ABEDINI S, HOLME I, FELLSTRÖM B, et al. Cerebrovascular events in renal transplant recipients[J]. Transplantation, 2009, 87(1):112-117. DOI: 10.1097/TP.0b013e31818bfce8.
|
[18] |
KUMAR S, DE LUSIGNAN S, MCGOVERN A, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care[J]. BMJ, 2018, 360:k342. DOI: 10.1136/bmj.k342.
|
[19] |
FINDLAY M, MACISAAC R, MACLEOD MJ, et al. Renal replacement modality and stroke risk in end-stage renal disease-a national registry study[J]. Nephrol Dial Transplant, 2018, 33(9):1564-1571. DOI: 10.1093/ndt/gfx291.
|
[20] |
PIZZI M, NG L. Neurologic complications of solid organ transplantation[J]. Neurol Clin, 2017, 35(4):809-823. DOI: 10.1016/j.ncl.2017.06.013.
|
[21] |
中华医学会器官移植学分会.器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J].器官移植, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition)[J]. Organ Transplant, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.
|
[22] |
ARNOLD R, PUSSELL BA, PIANTA TJ, et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients[J]. Am J Transplant, 2013, 13(9):2426-2432. DOI: 10.1111/ajt.12324.
|
[23] |
COLES A. Neurologic complications in organ transplant recipients[J]. J Neurol Neurosurg Psychiatry, 2000, 68(1):123. DOI: 10.1136/jnnp.68.1.123c.
|
[24] |
CIRIACO M, VENTRICE P, RUSSO G, et al. Corticosteroid-related central nervous system side effects[J]. J Pharmacol Pharmacother, 2013, 4(Suppl 1): S94-S98. DOI: 10.4103/0976-500X.120975.
|
[25] |
FURUKAWA M, TERAE S, CHU BC, et al. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging[J]. Neuroradiology, 2001, 43(8):615-621. doi: 10.1007/s002340100545
|
[26] |
GAUTAM A. Gastrointestinal complications following transplantation[J]. Surg Clin North Am, 2006, 86(5):1195-1206, vii. doi: 10.1016/j.suc.2006.06.006
|
[27] |
SEN A, CALLISEN H, LIBRICZ S, et al. Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal[J]. Crit Care Clin, 2019, 35(1): 169-186. DOI: 10.1016/j.ccc.2018.08.011.
|
[28] |
LUCAN VC, BERARDINELLI L. Gastrointestinal side effects of post-transplant therapy[J]. J Gastrointestin Liver Dis, 2016, 25(3):367-373. DOI: 10.15403/jgld. 2014.1121.253.ptt.
|
[29] |
SU VCH, GREANYA ED, ENSOM MH. Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: a systematic review[J]. Ann Pharmacother, 2011, 45(2):248-257. DOI: 10.1345/aph.1P456.
|
[30] |
DAVIES NM, GRINYÓ J, HEADING R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal[J]. Nephrol Dial Transplant, 2007, 22(9):2440-2448. doi: 10.1093/ndt/gfm308
|
[31] |
ROUSE GE, HARDINGER K, TSAPEPAS D, et al. A comparison of histamine receptor antagonists versus proton pump inhibitor gastrointestinal ulcer prophylaxis in kidney transplant recipients[J]. Prog Transplant, 2017, 27(1):4-9. DOI: 10.1177/1526924816669725.
|
[32] |
GUO YW, GU HY, ABASSA KK, et al. Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients[J]. World J Gastroenterol, 2016, 22(24):5616-5622. DOI: 10.3748/wjg.v22.i24.5616.
|
[33] |
中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年, 西安)[J].中华消化杂志, 2016, 36(8):508-513. DOI:10. 3760/cma.j.issn.0254-1432.2016.08.003.
Editorial Committee of Chinese Journal of Digestion. Specification for diagnosis and treatment of peptic ulcer (Xi' an, 2016)[J]. Chin J Digest, 2016, 36(8):508-513. DOI: 10.3760/cma.j.issn.0254-1432.2016.08.003.
|
[34] |
MALYSZKO J, OBERBAUER R, WATSCHINGER B. Anemia and erythrocytosis in patients after kidney transplantation[J]. Transpl Int, 2012, 25(10):1013-1023. DOI: 10.1111/j.1432-2277.2012.01513.x
|
[35] |
REINDL-SCHWAIGHOFER R, OBERBAUER R. Blood disorders after kidney transplantation[J]. Transplant Rev (Orlando), 2014, 28(2):63-75. DOI: 10.1016/j.trre. 2013.10.001.
|
[36] |
MUIRHEAD N. Erythropoietin and renal transplantation[J]. Kidney Int Suppl, 1999, 69:S86-S92. http://d.old.wanfangdata.com.cn/Periodical/dsjydxxb200404016
|
[37] |
CAMPISTOL JM, SCHENA FP. Kaposi' s sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors[J]. Nephrol Dial Transplant, 2007, 22(Suppl 1):i17- i 22. http://cn.bing.com/academic/profile?id=e71b6d7585c8e1aadd57e87089d29758&encoded=0&v=paper_preview&mkt=zh-cn
|
[38] |
DRENO B. Skin cancers after transplantation[J]. Nephrol Dial Transplant, 2003, 18(6):1052-1058. doi: 10.1093/ndt/gfg023
|
[39] |
PONTICELLI C, CUCCHIARI D, BENCINI P. Skin cancer in kidney transplant recipients[J]. J Nephrol, 2014, 27(4):385-394. DOI: 10.1007/s40620-014-0098-4.
|
[40] |
HOSSEINI-MOGHADDAM SM, SOLEIMANIRAHBAR A, MAZZULLI T, et al. Post renal transplantation Kaposi' s sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy[J]. Transpl Infect Dis, 2012, 14(4):338-345. DOI: 10.1111/j.1399-3062.2011.00714.x.
|
[41] |
STOFF B, SALISBURY C, PARKER D, et al. Dermatopathology of skin cancer in solid organ transplant recipients[J]. Transplant Rev (Orlando), 2010, 24(4):172-189. DOI: 10.1016/j.trre.2010.05.002.
|